Analysis supports MRD as a predictive marker for survival in AML, indicating its potential as a trial endpoint.
Measurable residual disease (MRD) is associated with survival in acute myeloid leukemia (AML) but is not an accepted trial endpoint. A new study that combined data from seven clinical trials found that MRD predicted individual survival within trials and correlated with overall survival across trials. The results support use of MRD as a surrogate endpoint for AML trials.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: